APLT Logo

Applied Therapeutics, Inc. (APLT) 

NASDAQ
Market Cap
$1.12B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
262 of 776
Rank in Industry
152 of 433

Largest Insider Buys in Sector

APLT Stock Price History Chart

APLT Stock Performance

About Applied Therapeutics, Inc.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III …

Insider Activity of Applied Therapeutics, Inc.

Over the last 12 months, insiders at Applied Therapeutics, Inc. have bought $65,367 and sold $9.37M worth of Applied Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Applied Therapeutics, Inc. have bought $820,285 and sold $8.73M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Kanter Stacy J. (director) — $65,367.

The last purchase of 30,000 shares for transaction amount of $65,367 was made by Kanter Stacy J. (director) on 2023‑12‑01.

List of Insider Buy and Sell Transactions, Applied Therapeutics, Inc.

2024-08-22SaleChief Medical Officer
22,681
0.0206%
$5.83$132,230+40.36%
2024-08-22SaleChief Financial Officer
13,530
0.0123%
$5.83$78,880+40.36%
2024-08-14SalePresident and CEO
119,591
0.1056%
$5.93$709,1750.00%
2024-08-13SalePresident and CEO
357,423
0.3288%
$6.18$2.21M0.00%
2024-08-12SalePresident and CEO
300,000
0.267%
$5.98$1.79M+32.08%
2024-06-06SalePresident and CEO
61,795
0.0519%
$4.32$266,954+30.89%
2024-06-06SaleChief Medical Officer
22,003
0.0185%
$4.32$95,053+30.89%
2024-06-06SaleChief Financial Officer
16,980
0.0143%
$4.32$73,354+30.89%
2024-06-05Sale10 percent owner
150,000
0.1261%
$4.24$636,000+33.26%
2024-06-04Sale10 percent owner
150,000
0.131%
$4.21$631,500+39.91%
2024-03-14SalePresident and CEO
318,573
0.2652%
$5.39$1.72M-3.95%
2024-03-14SaleChief Medical Officer
110,804
0.0922%
$5.39$597,234-3.95%
2024-03-14SaleChief Commercial Officer
48,871
0.0407%
$5.39$263,415-3.95%
2024-03-14SaleChief Financial Officer
28,727
0.0239%
$5.39$154,839-3.95%
2023-12-01Purchasedirector
30,000
0.0358%
$2.18$65,367+109.96%
2023-11-30SalePresident and CEO
3,968
0.0048%
$1.97$7,817+143.03%
2023-11-30SaleChief Medical Officer
1,583
0.0019%
$1.97$3,119+143.03%
2023-11-30SaleChief Commercial Officer
965
0.0012%
$1.97$1,901+143.03%
2023-11-03Sale10 percent owner
143,450
0.2215%
$2.31$331,370+100.00%
2023-11-02Sale10 percent owner
103,808
0.1662%
$2.32$240,835+104.76%

Insider Historical Profitability

10.44%
ALEXANDRIA REAL ESTATE EQUITIES, INC.10 percent owner
5855077
5.0982%
$9.7226+18.45%
Shendelman ShoshanaPresident and CEO
4690839
4.0845%
$9.72615+32.1%
Perfetti RiccardoChief Medical Officer
986853
0.8593%
$9.72159<0.0001%
Kanter Stacy J.director
63000
0.0549%
$9.7230<0.0001%
MARCUS JOEL Sdirector
365360
0.3181%
$9.7223+10.6%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Franklin Templeton Investments$71.84M9.2410.56M+50.53%+$24.12M0.02
Vr Adviser Llc$61.71M7.949.07M+45.2%+$19.21M3
Perceptive Advisors$54.43M7.018.01M+96.19%+$26.69M0.04
Janus Henderson$43.56M5.616.41M+198.57%+$28.97M0.02
Tupelo Capital Management LLC$37.91M4.885.57M+1.83%+$679,999.990.93
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.